SHANGHAI and HONG KONG, Feb. 25, 2026 /PRNewswire/ — Antengene Corporation Limited  (“Antengene”, SEHK: 6996.HK) , a leading innovative, commercial-stage global biotech company dedicated to discovering, developing and commercializing first-in-class and/or best-in-class medicines for autoimmune diseases, solid tumors and hematological malignancies, announced that it has entered into a clinical collaboration agreement with Shanghai Junshi Biosciences Co., Ltd (“Junshi Biosciences”, SEHK: 1877.HK; SSE: 688180). Under the collaboration, the parties will jointly evaluate the synergistic therapeutic potential of Antengene’s ATG-037, an oral small-molecule CD73 inhibitor, in combination with Junshi Biosciences’ JS207, a recombinant humanized anti-PD-1/VEGF bispecific antibody, in patients with solid tumors in Mainland China, with the goal of identifying clinical signals across multiple tumor types.

This collaboration builds on the encouraging Phase I proof-of-concept clinical data generated with ATG-037. At a time when resistance to checkpoint inhibitors (CPIs) has become a major clinical challenge, the Phase I study evaluating ATG-037 in combination with CPIs has already demonstrated promising potency into reversing CPI resistance. Beyond validating the synergistic potential of these two innovative drugs, this collaboration aims to advance the efficacy of existing immunotherapies and extend the overall survival (OS) of cancer patients through a “triple-axis” approach that incorporates immune checkpoint signalling, anti-angiogenesis, and the alleviation of adenosine-mediated immunosuppression.

ATG-037, Antengene’s orally administered small-molecule CD73 inhibitor, offers significant advantages over anti-CD73 monoclonal antibodies. In preclinical studies, ATG-037 demonstrated stronger inhibition of cell-surface CD73 enzymatic activity and overcame the “hook effect” commonly observed with antibody-based approaches. In addition, ATG-037’s higher tissue penetration compared with antibodies may facilitate complete CD73 inhibition at the cellular level. ATG-037 has demonstrated encouraging clinical activity in combination with anti–PD-1 therapy in patients with CPI-resistant melanoma and non-small cell lung cancer (NSCLC), based on the latest data presented at Antengene’s R&D Day in November 2025. In the ongoing Phase I/Ib STAMINA-01 study, the combination achieved an objective response rate (ORR) of 33.3% with a disease control rate (DCR) of 100% in patients with CPI-resistant melanoma, and an ORR of 21.4% with a DCR of 71.4% in patients with CPI-resistant NSCLC. The dataset was generated in Australia in patients with CPI-refractory solid tumors, with pembrolizumab and/or nivolumab as the predominant prior anti–PD-1 therapies, and more than 70% of melanoma patients were refractory to both anti–PD-1 and anti–CTLA-4 (ipilimumab). These results support ATG-037’s clinically meaningful activity across multiple tumor types, particularly in patients with prior immunotherapy resistance. Importantly, ATG-037 has demonstrated a favorable safety and tolerability profile in combination treatment, with no new or unexpected safety signals observed, including in patients receiving long-term therapy. Grade 3 or higher treatment-related adverse events only occurred in 7.9% of patients. Responses have also shown encouraging durability, including a patient who achieved a complete response and has remained on study for over three years and is currently receiving ATG-037 monotherapy for more than a year, as well as multiple patients with durations of response exceeding 12 months. These data support ATG-037’s potential role as a backbone agent for next-generation immuno-oncology combination regimens.

JS207, Junshi Biosciences’ independently developed recombinant humanized anti-PD-1/VEGF bispecific antibody, has demonstrated promising anti-tumor activity and a manageable safety profile in both preclinical and clinical studies. JS207’s preclinical studies demonstrated its robust anti-tumor efficacy in multiple tumor models and supported a differentiated mechanism of action, with VEGFA shown to enhance JS207’s antigen binding activity, T-cell activation potency and internalization of cell-surface PD-1. In a poster presented at ESMO Asia 2025, JS207 monotherapy showed encouraging efficacy across solid tumors. 62 patients with PD-L1 positive NSCLC received JS207 monotherapy as first-line treatment, and achieved an ORR of 58.1% and a DCR of 87.1%. Clinical activity has also been observed in additional tumor types, including hepatocellular carcinoma (HCC) and renal cell carcinoma (RCC), supporting the potential of PD-1/VEGF dual targeting across multiple tumor settings. To date, JS207 has 11 ongoing phase II clinical studies, exploring its use in combination with chemotherapy, monoclonal antibodies, antibody-drug conjugates (ADCs) and other drugs in NSCLC, colorectal cancer, triple-negative breast cancer, liver cancer and other tumor types, with nearly 500 patients enrolled. Based on the accumulated data from these studies, the U.S. Food and Drug Administration (FDA) has approved the investigational new drug (IND) application, allowing Junshi Biosciences to initiate an open-label, two-arm, randomized, active-controlled, Phase II/III clinical study comparing JS207 to nivolumab for the neoadjuvant treatment of patients with stage II/III, resectable, actionable genomic aberration (AGA)-negative NSCLC.

The scientific rationale for the collaboration is based on the complementary and potentially synergistic mechanisms of CD73 inhibition and dual PD-1/VEGF targeting. CD73 is recognized as a key regulator of immune suppression and angiogenesis within the tumor microenvironment through the generation of adenosine, which can dampen anti-tumor immune responses. In both clinical and preclinical settings, CD73 inhibitors have demonstrated meaningful synergy with anti–PD-1 monoclonal antibodies. In addition, CD73 activity has been shown to promote angiogenesis, including through upregulation of VEGF signaling, and may contribute to the development of resistance to anti-VEGF therapies. Given the broad relevance of immune suppression, angiogenesis and adenosine signaling across solid tumors, this combination strategy has the potential to be applicable across multiple tumor types. Taken together, these observations suggest that combining CD73 blockade with PD-1/VEGF-directed approaches has the potential to enhance and sustain therapeutic effects. Together, the combination of ATG-037 with JS207 represents a potential “triple-axis” approach that simultaneously modulates immune checkpoint signaling, angiogenesis, and the adenosine pathway. With the potential to deepen responses while maintaining a favorable safety profile, the combination of ATG-037 with JS207 may further improve the durability of benefit and may translate into improved OS.

We look forward to working closely with Junshi Biosciences and leveraging our respective expertise in target biology and clinical development to accelerate the evaluation of ATG-037 in combination with JS207 across multiple solid tumor types, with the goal of identifying clinical signals and delivering more innovative treatment options for patients in Mainland China.

About Antengene

Antengene Corporation Limited (“Antengene”, SEHK: 6996.HK) is a global, R&D-driven, commercial-stage biotech company focused on developing first-in-class/best-in-class therapeutics for diseases with significant unmet medical needs. Its pipeline spans from preclinical to commercial stages and includes several in-house discovered programs, including ATG-022 (CLDN18.2 ADC), ATG-037 (oral CD73 inhibitor), ATG-101 (PD-L1 x 4-1BB bispecific antibody), ATG-031 (CD24-targeting macrophage activator), and ATG-042 (oral PRMT5-MTA inhibitor).

Antengene has also developed AnTenGager™, a proprietary T cell engager 2.0 platform featuring “2+1” bivalent binding for low-expressing targets, steric hindrance masking, and proprietary CD3 sequences with fast on/off kinetics to minimize cytokine release syndrome (CRS) and enhance efficacy. These characteristics support the platform’s broad applicability across autoimmune disease, solid tumors and hematological malignancies indications.

To date, Antengene has obtained 32 investigational new drug (IND) approvals in the U.S. and Asia, and submitted new drug applications (NDAs) in 11 Asia Pacific markets. Its lead commercial asset, XPOVIO^® (selinexor), is approved in Mainland of China, Taiwan China, Hong Kong China, Macau China, South Korea, Singapore, Malaysia, Thailand, Indonesia and Australia, and has been included in the national insurance schemes in five of these markets (Mainland of China, Taiwan China, Australia, South Korea and Singapore).

Forward-looking statements

The forward-looking statements made in this article relate only to the events or information as of the date on which the statements are made in this article. Except as required by law, we undertake no obligation to update or revise publicly any forward-looking statements, whether as a result of new information, future events or otherwise, after the date on which the statements are made or to reflect the occurrence of unanticipated events. You should read this article completely and with the understanding that our actual future results or performance may be materially different from what we expect. In this article, statements of, or references to, our intentions or those of any of our Directors or our Company are made as of the date of this article. Any of these intentions may alter in light of future development. For a further discussion of these and other factors that could cause future results to differ materially from any forward-looking statement, please see the other risks and uncertainties described in the Company’s Annual Report for the year ended December 31, 2024, and the documents subsequently submitted to the Hong Kong Stock Exchange.

For more information, please contact:

Investor Contacts: 
Donald Lung
E-mail: donald.lung@antengene.com  

BD Contacts:
Ariel Guo
E-mail: ariel.guo@antengene.com

Source

Source: Graphy Inc.

Source

HONG KONG, Feb. 24, 2026 /PRNewswire/ — Hong Kong is a world-renowned food paradise, offering everything from local snacks like fish balls and egg waffles to Michelin-starred culinary experiences. However, maintaining a healthy weight amidst fast-paced lifestyles, high pressure, and even genetic factors has become a relentless battle. Excessive fat accumulation poses significant health risks, and even those with a seemingly slender physique can fall into the trap of obesity. Today, obesity is no longer just a cosmetic concern; it is classified as a chronic, relapsing disease by the World Health Organization (WHO). Thus, weight loss and anti-obesity measures are now essential strategies for preserving health, not just for aesthetic reasons.

To deepen public understanding of the health threats posed by obesity, Novo Nordisk Hong Kong—driven by its commitment as a leader and pioneer in obesity management—is proud to support the “Anti-Obesity Health Base” campaign. This event offers the public the opportunity to learn about their true weight health status, while also understanding the associated harms and complications of obesity through engaging virtual games and informative exhibits. Adding a unique layer of local charm, the campaign features exclusive illustrations by the beloved homegrown illustrator brand “Maggiemarket.” From interactive games and photo spots to the exhibition zones, Maggiemarket’s playful characters will be there to guide and entertain participants throughout the entire experience.

Anti-Obesity Health Base
Location: Atrium, K11 Art Mall, 18 Hanoi Rd, Tsim Sha Tsui
Opening Hours: February 24 (TUE) to March 4 (WED), 2026, from 12 PM to 8 PM
Event Highlights:

• Maggiemarket photo spots
• Body mass index (BMI) & waist measurement station
• Interactive games, exciting prizes, and an instant photo booth
• Complimentary anti-obesity four-frame photo booth experience*
• Souvenir giveaways, including anti-obesity motivational keychains*
  *Limited quantities available; first-come, first-served until supplies last

How Common is Obesity in Hong Kong?
Obesity is a widespread issue in Hong Kong and around the world. According to the Department of Health, over half of the local population aged 15 and above are classified as overweight or obese, with approximately 44% of those aged 25 to 34 and over 61% in middle age^[1]. In Hong Kong, an adult is considered overweight with a BMI of 23 to 25, while a BMI over 25 classifies them as obese^[2].

Additionally, central obesity can occur even with a normal BMI. Waist circumference is a key indicator: a measurement of 90 cm (35.4 inches) or more for men, or 80 cm (31.5 inches) or more for women, may signal obesity risks^{[4] & [6]}.

Globally, the scale is immense. WHO data shows that over 2.5 billion adults are overweight or obese, a condition that also affects nearly 450 million children and adolescents aged 5 to 19^[3].

Why Should Obesity Be Addressed as a Disease?
Many dismiss obesity as merely an issue of appearance, but it is often the root of numerous health issues. Increasing evidence shows that obese individuals are at a higher risk for several conditions, including hypertension, arthritis, fatty liver, diabetes, dyslipidemia, chronic kidney disease, sleep apnea, metabolic syndrome, and even multiple types of cancer^{[4] & [5]}. The global toll is severe: in 2021 alone, high BMI was linked to 3.7 million deaths worldwide^[3].

Moreover, obesity imposes a heavy psychological and functional burden. It can lead to breathing difficulties, mobility issues, back pain, sleep disorders, fatigue, reduced productivity, depression, and anxiety^[5]—impeding daily life, work, and social interactions.

Why Is Weight Control Crucial for Health?
Weight gain is often the result of an imbalance between calorie intake and expenditure, influenced by a complex mix of genetic, environmental, psychological, and social factors^[3].

Since obesity arises from multiple factors, simply dieting and exercising may not be sufficient to overcome it. Seeking professional medical advice can help achieve effective and targeted weight management. WHO has also included safe and effective pharmacotherapy as one of the recommended options within comprehensive obesity management guidelines^[3].

Join the Anti-Obesity Health Base Together!
Supported by Novo Nordisk Hong Kong, the Anti-Obesity Health Base aims to raise awareness of obesity and encourage everyone to fight against it!

The Anti-Obesity Health Base is divided into various zones, offering a range of activities and information:

• BMI & Waist Measurement Station: Even if you appear slim, the results may surprise you! Let’s find out if you’re at risk. Get your BMI and waist circumference measured to reveal hidden risks like central obesity that aren’t visible.
• Interactive Games (Pedaling in Place & “Weight No More” Health Defender): Understand how obesity is linked to serious diseases. Play our immersive virtual games to battle obesity-related health risks and learn about the various conditions it can cause.
• “Guess Who Has Obesity?” Exhibition: Listen to personal stories from different patients. Guess who is obese, challenging the assumption that health status can be judged by appearance alone.
• Giant Capsule Toy Machine: Discover the real impact of obesity on physical and mental health through educational videos. Try your luck at the capsule toy machine to win prizes like keychains featuring our “Anti-Obesity” slogans.
• Maggiemarket Photo Spots: Capture the moment with a complimentary four-frame photo at our themed booth. Limited quantities available, first-come, first-served.

The Anti-Obesity Health Base is all set and invites everyone to join us. It’s time to truly understand obesity, recognize your personal risks, and take proactive steps to tackle obesity for your health!

Source

– Operated promotional booth at Japan’s largest food and retail exhibition from Feb. 18–20, attracting approximately 10,000 visitors over three days
– Promoted K-food with Jongga and O’food brands; four tasting menus reflecting local food trends received favorable reviews

SEOUL, South Korea, Feb. 24, 2026 /PRNewswire/ — Daesang announced on the 23rd that it successfully concluded its first participation in the “Supermarket Trade Show 2026 (SMTS 2026),” Japan’s largest food and retail exhibition, held for three days from February 18 to 20 in Chiba Prefecture, Japan.

Hosted by the New Supermarket Association of Japan, SMTS 2026 is the country’s largest specialized exhibition for the food and retail industry, offering a comprehensive view of the latest trends in the Japanese distribution sector. Celebrating its 60th anniversary this year, the exhibition recorded its largest scale ever, with approximately 2,200 companies from 16 countries participating and around 83,000 visitors in attendance.

Marking its first appearance at the event, Daesang highlighted its No.1* kimchi brand “Jongga” and global food brand “O’food,” successfully promoting its differentiated K-food competitiveness rooted in advanced fermentation technology and reinforcing its position as Korea’s leading comprehensive food company.

*Source: NIELSEN KOREA 2007–2024 Kimchi Sales Volume & Value

During the exhibition, Daesang’s booth attracted approximately 10,000 visitors, drawing significant attention. The company held business meetings with representatives from major Japanese retailers and regional supermarket chains, including AEON, Costco, and Ministop. Amid strong interest from global retail buyers, Daesang engaged in detailed discussions toward new supply agreements, achieving tangible business outcomes.

Products showcasing the expertise of one of the world’s leading fermentation specialists garnered particular attention, especially kimchi and traditional Korean sauces. As Japan’s kimchi consumption trend shifts from non-fermented to fermented varieties, distributors expressed strong interest in listing “Ilpum Kimchi,” which delivers the authentic taste of traditional Korean fermented kimchi. In addition, “O’food Gochujang,” crafted using traditional methods inherited from Sunchang—the birthplace of Korean jang (fermented sauces)—also drew keen interest.

The tasting program, designed to reflect local food culture trends, proved to be a major highlight. Under the concept of “Delica” foods—ready-to-eat and ready-to-cook items that are increasingly popular in Japanese supermarkets—Daesang introduced four trendy menu items utilizing kimchi and gochujang: Stir-fried Kimchi Egg Gimbap, Water Parsley Gochujang Shrimp Gangjeong, Kimchi Tuna Mayo Sandwich, and Gochujang Nikujaga. These dishes demonstrated how kimchi and gochujang can easily enhance umami flavors in everyday meals. All 2,400 servings of the four featured tasting menus were completely sold out, along with an additional 2,600 servings of Mat Kimchi and Dubu Kimchi prepared for sampling.

Chiharu Asao, a Japanese food influencer who developed the tasting menu, commented, “We created a fusion dish by adding kimchi to tamagoyaki, a familiar Japanese egg dish, ensuring that the spiciness and umami of Ilpum Kimchi harmonize with the soft texture of the egg. Although some visitors were initially unfamiliar with the idea of kimchi in a sandwich, they were pleasantly surprised by how well the flavors complemented each other after tasting it.”

The booth, designed to embody Daesang’s corporate vision, also drew significant attention. Featuring a distinctive design inspired by tree rings, a large LED screen, and a space replicating a Japanese supermarket display, the booth stood out prominently within the exhibition hall. Brochures and tasting containers incorporating traditional Korean mother-of-pearl craftsmanship further conveyed the company’s dedication and authenticity in fermented foods.

Visitors shared positive feedback, commenting, “The red booth design reminiscent of kimchi was impressive,” “The mother-of-pearl design elegantly captured Korean aesthetics,” and “The harmony with Japanese cuisine exceeded expectations,” adding to the vibrant atmosphere on site.

Lim Jung-bae, CEO of Daesang Corporation, stated, “Our participation in SMTS 2026 served as an important opportunity to reaffirm the status of fermented foods—the core of K-food—in the Japanese market and to expand our local distribution network. Moving forward, we will continue to introduce innovative products tailored to the lifestyles of local consumers, led by Jongga and O’food, to further strengthen our presence in Japan.”

Founded 70 years ago, Daesang has been strengthening its global competitiveness. The company established Daesang Japan Inc. in 1978 to formally enter the Japanese market. Currently, it exports a wide range of products, including kimchi, seasonings, traditional sauces, sauces, and ready-to-eat meals. In 2023, it established Daesang Foods Japan Inc. to secure local production capabilities. In addition, last year the company hosted the “Kimchi Blast Tokyo 2025” pop-up event on Cat Street in Shibuya, Tokyo, blending Korean kimchi culture with Japanese lifestyle trends and expanding consumer engagement in the local market.

Source